Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Allory

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Clinical Genetics|March 17, 2017
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriersM Muller, S Ferlicot, M Guillaud-Bataille, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]I Durand-Zaleski, H Rabetrano, M Devonec, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]Y Neuzillet, S Rebouissou, A De Reynies, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classificationK Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentD Pouessel, Y Neuzillet, L S Mertens, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Clinical Genetics|March 17, 2017
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriersM Muller, S Ferlicot, M Guillaud-Bataille, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]I Durand-Zaleski, H Rabetrano, M Devonec, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]Y Neuzillet, S Rebouissou, A De Reynies, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classificationK Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentD Pouessel, Y Neuzillet, L S Mertens, et al.
Pageof 5